Literature DB >> 18537540

Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses.

Waldo Cerpa1, Margarita C Dinamarca, Nibaldo C Inestrosa.   

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid beta-peptide (Abeta). All converging lines of evidence suggest that progressive accumulation of the Abeta plays a central role in the genesis of Alzheimer's disease and it was long understood that Abeta had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Abeta fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Abeta fibrils formation and depolymerizate Abeta fibrils also. Over the past decade, data have emerged from the use of several sources of Abeta (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Abeta oligomers are also injurious. Accumulating evidence suggests that soluble forms of Abeta are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, beta-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Abeta revealed a significant dose-dependent decrease in the levels of cytosolic beta-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Abeta, therefore the activation of Wnt signaling protects against the Abeta neurotoxicity. Here we review recent progress about Abeta structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Abeta oligomers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537540     DOI: 10.2174/156720508784533321

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  37 in total

1.  Neurogenesis in Alzheimer´s disease: a realistic alternative to neuronal degeneration?

Authors:  Rocío E Gonzalez-Castaneda; Alma Y Galvez-Contreras; Sonia Luquín; Oscar Gonzalez-Perez
Journal:  Curr Signal Transduct Ther       Date:  2011-09-01

2.  Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease.

Authors:  Margarita C Dinamarca; Juan P Sagal; Rodrigo A Quintanilla; Juan A Godoy; Macarena S Arrázola; Nibaldo C Inestrosa
Journal:  Mol Neurodegener       Date:  2010-01-18       Impact factor: 14.195

3.  Wnt-5a occludes Abeta oligomer-induced depression of glutamatergic transmission in hippocampal neurons.

Authors:  Waldo Cerpa; Ginny G Farías; Juan A Godoy; Marco Fuenzalida; Christian Bonansco; Nibaldo C Inestrosa
Journal:  Mol Neurodegener       Date:  2010-01-18       Impact factor: 14.195

4.  Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca²⁺/Calmodulin-dependent protein kinase II.

Authors:  Lorenza Ciani; Kieran A Boyle; Ellen Dickins; Macarena Sahores; Derek Anane; Douglas M Lopes; Alasdair J Gibb; Patricia C Salinas
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 5.  Spreading of Pathology in Alzheimer's Disease.

Authors:  Zhong-Yue Lv; Chen-Chen Tan; Jin-Tai Yu; Lan Tan
Journal:  Neurotox Res       Date:  2017-06-16       Impact factor: 3.911

6.  Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.

Authors:  Marcella Reale; Marta Di Nicola; Lucia Velluto; Chiara D'Angelo; Erica Costantini; Debomoy K Lahiri; Mohammad A Kamal; Qian-sheng Yu; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

Review 7.  Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Authors:  J S Malter; B C Ray; P R Westmark; C J Westmark
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

8.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

9.  Synapse stability in the precuneus early in the progression of Alzheimer's disease.

Authors:  Stephen W Scheff; Douglas A Price; Frederick A Schmitt; Kelly N Roberts; Milos D Ikonomovic; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 10.  RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?

Authors:  Shi Du Yan; Angelika Bierhaus; Peter P Nawroth; David M Stern
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.